Edition:
India

China Biologic Products Holdings Inc (CBPO.OQ)

CBPO.OQ on NASDAQ Stock Exchange Global Select Market

75.90USD
12 Dec 2017
Change (% chg)

$-2.27 (-2.90%)
Prev Close
$78.17
Open
$78.36
Day's High
$78.77
Day's Low
$75.79
Volume
27,074
Avg. Vol
111,993
52-wk High
$120.01
52-wk Low
$74.01

Latest Key Developments (Source: Significant Developments)

China Biologic posts Q3 adj. earnings per share $1.38
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - China Biologic Products Holdings Inc :China Biologic reports unaudited financial results for the third quarter of 2017.Q3 adjusted non-GAAP earnings per share $1.38.Q3 earnings per share $1.11.Q3 sales rose 15.1 percent to $99.6 million.China Biologic Products Holdings Inc - ‍reiterates full year non-GAAP adjusted net income forecast​.China Biologic Products Holdings - ‍adjusting FY 2017 forecast of total sales growth to 9 pct-10 pct in RMB terms compared to previous estimates of 13 pct-15 pct​.  Full Article

China Biologic agrees to acquire Tianxinfu from PWM
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - China Biologic Products Holdings Inc :China Biologic agrees to acquire Tianxinfu from PWM.China Biologic Products Holdings Inc - ‍It has agreed to acquire 80% equity interest in Tianxinfu (Beijing) Medical Appliance Co., Ltd​.China Biologic Products - ‍In exchange for acquisition of 80% equity interest in Tianxinfu from PWM, Cbpo will issue 5.5 million ordinary shares to PWM​.China Biologic Products - ‍PWM is expected to hold approximately 16.66% of outstanding share capital of Cbpo taking into effect new issuance​ post deal.China Biologic Products - Board determined to exempt deal from causing PWM to be deemed "acquiring person" under CBPO's preferred shares rights agreement​.China Biologic Products Holdings Inc - ‍Acquire 80% equity interest in Tianxinfu from PW Medtech Group Limited​.China Biologic Products - ‍CBPO elected to be exempted from shareholder approval requirement under applicable rules of nasdaq market for proposed deal.China Biologic Products Holdings - ‍Elected to be exempted from shareholder approval requirement under applicable rules of Nasdaq stock market for deal.China Biologic Products Holdings Inc - ‍Post deal close, PWM expected to hold about 16.66% of share capital of co taking into effect new issuance​.  Full Article

China Biologic receives approval for commercial manufacturing of human fibrinogen
Monday, 9 Oct 2017 

Oct 9 (Reuters) - China Biologic Products Holdings Inc :China Biologic receives approval for commercial manufacturing of human fibrinogen.China Biologic Products Holdings Inc - ‍expects first batch of products to be released to market by end of 2017​.China Biologic Products Holdings Inc - ‍expect to see meaningful profit contribution from fibrinogen in 2018​.China Biologic Products Holdings - unit received approval from China food and drug administration for commercial manufacturing of human fibrinogen.  Full Article

China Biologic says Min Fang resigned directorship
Monday, 15 Aug 2016 

China Biologic Products - : China Biologic announces change to board of directors . Min Fang, director associated with Warburg Pincus LLC, resigned his directorship of co with effect from August 15, 2016. .Warburg Pincus has reduced its holdings in company over last year and now hold less than 0.1% of co's outstanding common stock.  Full Article

Capital Research Global Investors reports 11.3 pct passive stake in China Biologic Products
Friday, 8 Jul 2016 

:Capital Research Global Investors reports a passive stake of 11.3% in China Biologic Products Inc as of June 30, 2016 - SEC Filing.  Full Article

China Biologic Products says secondary offering of 2.78 mln common shares
Friday, 3 Jun 2016 

China Biologic Products Inc : Says secondary offering 2.78 million common shares .China Biologic announces secondary offering of common stock.  Full Article

China Biologic Products Inc announces pricing of secondary offering of common stock
Wednesday, 2 Mar 2016 

China Biologic Products Inc:Pricing of a secondary offering of 3,870,000 shares of common stock at a price to public of $110 per share.  Full Article

BRIEF-China Biologic posts Q3 adj. earnings per share $1.38

* China Biologic reports unaudited financial results for the third quarter of 2017